HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

5- ((5- ((1,1'- biphenyl)- 4- yl)- 6- chloro- 1H- benzo(d)imidazol- 2- yl)oxy)- 2- methylbenzoic acid

Also Known As:

MK 3903; MK-3903; MK3903

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzimidazoles: 245
      - 5-((5-((1,1'-biphenyl)-4-yl)-6-chloro-1H-benzo(d)imidazol-2-yl)oxy)-2-methylbenzoic acid: 1
Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Biphenyl Compounds: 7
        5-((5-((1,1'-biphenyl)-4-yl)-6-chloro-1H-benzo(d)imidazol-2-yl)oxy)-2-methylbenzoic acid: 1

Experts

1.	Chen, Linlin: 1 article (08/2021)
2.	Chi, Mengyi: 1 article (08/2021)
3.	Guo, Cheng: 1 article (08/2021)
4.	Sun, Xipeng: 1 article (08/2021)
5.	Wan, Lili: 1 article (08/2021)
6.	Yang, Quanjun: 1 article (08/2021)
7.	Zhang, Hong: 1 article (08/2021)

Related Diseases

1.	Atrophy 08/01/2021 - "In DDP treated C2C12 myotubes, DAI could inhibit Glut4/AMPK/FoxO pathway to reduce myotubes atrophy, while AMPK agonist MK-3903 could reverse the protective effect of DAI. "